Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
NASDAQ:SYRS
Holding SYRS?
Track your performance easily
SYRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.43 - $8.17
Previous Close$3.23
Volume10.38M
Average Volume (3M)437.47K
Market Cap
$86.67M
Enterprise Value$88.62M
Total Cash (Recent Filing)$58.27M
Total Debt (Recent Filing)$60.23M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 06, 2025EPS Estimate
-$0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.03
Shares Outstanding26,832,457
10 Day Avg. Volume436,172
30 Day Avg. Volume437,474
Standard Deviation0.33
R-Squared0.06
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-6.66
Price to Sales (P/S)223.95
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue228.99
Enterprise Value/Gross Profit8.92
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$5.50Price Target Upside101.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Syros Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe SELECT-MDS-1 Phase 3 trial has passed an interim futility analysis, indicating that the trial should continue without modification.
Market PotentialManagement highlighted the large commercial opportunity for tamibarotene in RARA-positive HR-MDS, with a market opportunity of approximately $1.6 billion.
Therapeutic AdvancementsTamibarotene would be the first targeted therapy for the patient population, addressing the approximately 50% of patients with RARA overexpression.
Bears Say
Clinical TrialsThe discontinuation of enrollment in the SELECT-AML-1 Phase 2 study challenges the thesis and overall investor narrative regarding the program.
Revenue ImpactThe discontinuation of enrollment in SELECT-AML-1 led to the removal of all associated revenue from the valuation.
Trial ResultsSyros announced negative interim futility results from the SELECT-AML-1 trial for tamibarotene in newly diagnosed RARA positive, unfit AML patients.
---
Ownership Overview
12.39% Insiders
4.69% Mutual Funds
0.44% Other Institutional Investors
78.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was $1.43 and its highest was $8.17 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Currently, no data Available
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 103 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.676 by $0.516.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -$0.72.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.676. Following the earnings report the stock price went up 0.398%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Among the largest hedge funds holding Syros Pharmaceuticals’s share is Flagship Pioneering Inc.. It holds Syros Pharmaceuticals’s shares valued at 7M.
---
Syros Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (101.47% Upside)
$5.50 (101.47% Upside)
Blogger Sentiment
Bullish
SYRS Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $320.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.35%
12-Months-Change
Fundamentals
Return on Equity
-776.96%
Trailing 12-Months
Asset Growth
-42.49%
Trailing 12-Months
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
---
SYRS Earnings Call
Q3 2024
0:00 / 0:00
---
SYRS Stock 12 Month Forecast
Average Price Target
$5.50
▲(101.47% Upside)
Technical Analysis
Mersana Therapeutics
―
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering SYRS
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+4.60%
reiterated a buy rating 23 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.60% per trade.
---